4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
DVA - DaVita Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$235.67
DETAILS
HIGH:
$270.00
LOW:
$215.00
MEDIAN:
$222.00
CONSENSUS:
$235.67
UPSIDE:
33.80%
Stock News
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
In fact, it's a healthcare company. It is a strong player in its chosen niche.
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.
2,460,987 Shares in DaVita Inc. $DVA Purchased by BlackRock Inc.
BlackRock Inc. purchased a new position in DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,460,987 shares of the company's stock, valued at approximately $547,520,000. BlackRock Inc. owned approximately 3.86% of DaVita as of its most recent SEC filing.
Bank of New York Mellon Corp Makes New $101.13 Million Investment in DaVita Inc. $DVA
Bank of New York Mellon Corp purchased a new stake in DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 454,545 shares of the company's stock, valued at approximately $101,127,000. Bank of New York Mellon Corp owned approximately
Bank of America Corp DE Cuts Holdings in DaVita Inc. $DVA
Bank of America Corp DE lowered its position in shares of DaVita Inc. (NYSE: DVA) by 33.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,059 shares of the company's stock after selling 120,642 shares during
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
Dow Extends Record Run With Over 400-Point Pop
The Dow is up triple digits and trading at record highs as upbeat corporate earnings continue to roll in and lift Wall Street
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
DaVita Q2 Earnings Call Highlights
DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.
DaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic Execution Drive Confidence
Adjusted Operating Income: $579 million in Q2 2026.Adjusted Earnings Per Share: $4.02 in Q2 2026.Free Cash Flow: $256 million in Q2 2026.U.S. Dialysis Treatment
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped out of Obamacare plans following the end of pandemic-era subsidies.
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $4.01 per share. This compares to earnings of $2.95 per share a year ago.
Is DaVita Inc (DVA) Overvalued After Q2 Earnings Beat? EPS at $4.02 and Revenue at $3.554 Billion; GF Score: 86/100
On August 4, 2026, DaVita Inc (DVA) released its 8-K filing, revealing financial and operational results for the quarter ended June 30, 2026. As one of the larg
DaVita Inc. 2nd Quarter 2026 Results
DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier Rodriguez, CEO of DaVita Inc. "As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
Price Targets
DaVita price target lowered to $215 from $250 at Truist
$215.00
(was $179.93)
Truist Financial
TD Cowen Upgrades DaVita (DVA) to Buy
$220.00
(was $180.67)
Oppenheimer
TD Cowen Upgrades DaVita (DVA) to Buy
$220.00
(was $180.67)
Raymond James
DaVita price target raised to $265 from $220 at Deutsche Bank
$265.00
(was $185.53)
Pito Chickering
·
Deutsche Bank
DaVita price target raised to $224 from $218 at Barclays
$224.00
(was $227.99)
Andrew Mok
·
Barclays
DaVita price target raised to $250 from $205 at Truist
$250.00
(was $235.58)
Truist Financial
DaVita price target raised to $270 from $235 at UBS
$270.00
(was $229.48)
UBS
DaVita price target raised to $218 from $194 at Barclays
$218.00
(was $234.31)
Barclays
DaVita price target raised to $205 from $158 at Truist
$205.00
(was $194.38)
Truist Financial
DaVita price target raised to $194 from $158 at Barclays
$194.00
(was $193.88)
Andrew Mok
·
Barclays
DaVita upgraded to Buy from Hold at Deutsche Bank
$220.00
(was $157.04)
Pito Chickering
·
Deutsche Bank
DaVita price target raised to $158 from $128 at Truist
$158.00
(was $144.41)
Truist Financial
DaVita price target raised to $190 from $186 at UBS
$190.00
(was $134.73)
UBS
DaVita price target raised to $158 from $143 at Barclays
$158.00
(was $111.19)
Barclays
DaVita price target lowered to $143 from $149 at Barclays
$143.00
(was $126.56)
Barclays
DaVita price target lowered to $140 from $148 at Truist
$140.00
(was $123.36)
David MacDonald
·
Truist Financial
DaVita price target lowered to $149 from $160 at Barclays
$149.00
(was $127.89)
Andrew Mok
·
Barclays
DaVita price target lowered to $148 from $164 at Truist
$148.00
(was $129.54)
David MacDonald
·
Truist Financial
Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
$184.00
(was $142.40)
Lisa Bedell Clive
·
Bernstein
DaVita price target raised to $145 from $139 at BofA
$145.00
(was $133.53)
Kevin Fischbeck
·
Bank of America Securities